IMA Stock Summary and Trading Ideas (Imagenebio | NASDAQ:IMA)

ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.

Imagenebio trades on the NASDAQ stock market under the symbol IMA.

As of September 4, 2026, IMA stock price declined to $4.85 with 15,457 million shares trading.

IMA has a market cap of $55.05 million. This is considered a Micro Cap stock.

The top ETF exchange traded funds that IMA belongs to (by Net Assets): VTI, VXF.

IMA has underperformed the market in the last year with a price return of -42.6% while the SPY ETF gained +19.8%. IMA has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -14.8% and -12.0%, respectively, while the SPY returned +2.0% and +0.6%, respectively.

IMA support price is $4.59 and resistance is $5.18 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IMA shares will trade within this expected range on the day.